

Samvel B Gasparyan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692351/publications.pdf>

Version: 2024-02-01

9
papers

283
citations

1306789

7
h-index

1588620

8
g-index

9
all docs

9
docs citations

9
times ranked

359
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 586-594.	5.5	145
2	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 886-896.	2.2	40
3	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
4	Adjusted win ratio with stratification: Calculation methods and interpretation. <i>Statistical Methods in Medical Research</i> , 2021, 30, 580-611.	0.7	29
5	Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 765-787.	0.4	12
6	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 643-654.	2.2	10
7	Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 785-794.	0.8	9
8	Comments on "Sample size formula for a win ratio endpoint" by R. X. Yu and J. Ganju. <i>Statistics in Medicine</i> , 2022, 41, 2688-2690.	0.8	3
9	Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 98-99.	5.5	0